An interventional study of Camzyos (Mavacamten) in Hypertrophic Obstructive Cardiomyopathy \(HOCM\), Left Ventricular Outflow Tract Obstruction and Myocardial Ischaemia, sponsored by University of Manchester. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by University of Manchester · Not applicable, Interventional, and Treatment
Among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 3 open to participants now, 7 under way, 1 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.
Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one is the 11th largest by planned enrollment, is one of 3 that started in 2026, is one of 2 with no phase, and was the 20th registered.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
This study's planned enrollment of 75 is above the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Browse Cardiomyopathy, Hypertrophic studies →3 of the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Each count lists the studies.
MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →21 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2026.
Median enrollment 75 across the 21 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
17 of 21 have an industry lead sponsor. The 7 most frequent:
University of Manchester is the lead sponsor of 201 studies on the registry; 44 are open to participants now.
University of Manchester has 4 studies filed under Cardiomyopathy, Hypertrophic — fewer than ten, so there is no comparison to draw.
1 of the studies testing MYK-461 in Cardiomyopathy, Hypertrophic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07103655Second Affiliated Hospital, Zhejiang University, School of MedicineThe Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction | 2026-11-01 |
Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Hypertrophic obstructive cardiomyopathy (HOCM) is a heritable heart condition that leads to the thickening of the heart muscle and causes obstruction of blood flow, impeding it's ejection from the heart (LVOT obstruction). Often individuals with HOCM suffer from chest pain and shortness of breath due to lack of oxygen supply (ischaemia) to the heart muscle in the absence of blockages in the coronary arteries.
Despite proven advances in treatment of LVOT obstruction with the novel medication Camzyos (Mavacamten), there is a limited understanding of its effect on myocardial ischaemia.
This study, called the PEACH Trial, is designed to assess whether Camzyos also improves blood supply (perfusion) to the heart muscle in patients with HOCM. A specialised imaging technique called Positron Emission Tomography/Computed Tomography (PET-CT), using Rubidium-82 will be used to evaluate blood flow to the heart muscle before and after treatment. Camzyos is part of participants' regular clinical treatment and is not being supplied, administered, or influenced by the study in any way.
Participants with HOCM who are starting treatment with Camzyos as part of their clinical care will undergo a baseline PET-CT scan (if not already done), and a second scan after 12 months. The follow-up scan is done solely for research purposes. The scans will allow researchers to evaluate whether the medication improves myocardial perfusion in addition to relieving outflow obstruction.
The study is sponsored by the University of Manchester and funded by Bristol Myers Squibb. It will involve up to 75 participants recruited at Manchester University NHS Foundation Trust. The findings could help improve understanding of how Camzyos works and support personalised treatment approaches in HOCM.
The criteria were revised on the registry on Nov 4, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Contraindication to Rubidium PET-CT, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with Hypertrophic Obstructive Cardiomyopathy (HOCM) who are clinically prescribed Camzyos (Mavacamten) as part of standard care. Participants will undergo baseline(standard care) and 12-month follow-up (research scan) myocardial perfusion PET-CT scans to assess the effect of Camzyos on myocardial ischaemia.
Drug: Camzyos (Mavacamten)
Camzyos (Mavacamten), a selective cardiac myosin inhibitor prescribed as part of routine care in patients with symptomatic HOCM. The study evaluates its effect on myocardial perfusion over a 12-month period using PET-CT imaging.
Change in Myocardial Ischaemia:
This will be assessed using Rubidium PET-CT. Looking at change in parameters such as global myocardial blood flow reserve (GMBFR)
Time frame: 12 months
Change in Myocardial Ischaemia:
This will be assessed using Rubidium PET-CT. Looking at change in parameters such as global myocardial stress flow (GMSF).
Time frame: 12 months
Change in Myocardial Ischaemia:
This will be assessed using Rubidium PET-CT. Looking at change in parameters such as coronary flow capacity (CFC).
Time frame: 12 months
Patient-Reported Symptoms
Secondary outcomes: 1\. Patient-Reported Symptoms: • Angina and Shortness of Breath: Changes in the frequency and severity of angina episodes and shortness of breath will be documented using validated the Seattle Angina Questionnaire- 7 (SAQ). Seattle Angina Questionnaire-7 (SAQ-7, 2014 version): The SAQ-7 is a validated, patient-reported outcome measure assessing the impact of angina on health status. It consists of 7 items covering 3 domains: Physical Limitation, Angina Frequency, and Quality of Life. Each domain is scored on a 0-100 scale, where higher scores indicate better health status (less angina, fewer physical limitations, and improved quality of life). Scores are transformed according to published scoring algorithms. The SAQ-7 Summary Score is the mean of the 3 domain scores. Minimum score: 0 (worst possible angina-related health status) Maximum score: 100 (no angina, no limitation, best possible quality of life)
Time frame: 12 months
Patient-Reported Symptoms
Secondary outcomes: 1\. Patient-Reported Symptoms: * Angina and Shortness of Breath: Changes in the frequency and severity of angina episodes and shortness of breath will be documented using validated the the HCM Shortness of Breath Questionnaire (HCMSQ-SoB) (also used in the EXPLORER-HCM trial) * The HCMSQ total score is as the equally weighted sum of the three domain scores, i.e., the sum of the SoB domain score divided by four (items), the tiredness domain score (a single item), and the CV symptom domain score divided by three (items), if all three domain scores are calculated; otherwise, the HCMSQ total score is missing. The potential range of scores is 0-12.5, with lower scores indicating a lower presence of symptoms overall/better health.
Time frame: 12 months
Patient-Reported Symptoms
Secondary outcomes: NYHA Functional Class: Improvement in NYHA functional class will be evaluated to assess changes in functional capacity and symptom severity. New York Heart Association (NYHA) Functional Classification - Ordinal scale ranging from Class I (no symptoms and no limitation in ordinary physical activity) to Class IV (severe limitations; symptoms present even at rest). Lower classes indicate better functional status, and improvement is reflected by a decrease in NYHA class from baseline.
Time frame: 12 months
Subgroup Analyses
Differences in Efficacy Based on Patient Subgroups: • Subgroup Analyses: The study will investigate differences in the impact of Mavacamten on myocardial ischemia and symptoms based on: o Age years (younger vs. older patients)
Time frame: 12 months
Subgroup Analyses
Differences in Efficacy Based on Patient Subgroups: • Subgroup Analyses: The study will investigate differences in the impact of Mavacamten on myocardial ischemia and symptoms based on: o Sex (male vs. female)
Time frame: 12 months
Subgroup Analyses
Differences in Efficacy Based on Patient Subgroups: • Subgroup Analyses: The study will investigate differences in the impact of Mavacamten on myocardial ischemia and symptoms based on: o Genetic Status (gene-positive vs. gene-negative vs VUS)
Time frame: 12 months
Subgroup Analyses
Differences in Efficacy Based on Patient Subgroups: • Subgroup Analyses: The study will investigate differences in the impact of Mavacamten on myocardial ischemia and symptoms based on: o Baseline LVOT Gradient Levels (mmHg) (higher vs. lower LVOT gradients)
Time frame: 12 months
Plan to share: No — Data access is limited to the research team as per ethical and institutional approvals.
Started Mar 2026 (actual). Primary completion is estimated for Oct 2028, 31 months after the start.
Of 47 non-industry interventional studies with no phase under Cardiomyopathy, Hypertrophic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's planned 31 months is below that.
Counting every sponsor, half of 52 studies reached it within 52 months; a quarter within 26 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MYK-461
Cardiomyopathy, Hypertrophic →